Epcoritamab Medicine 04 December 2025 Extended indication 2L Follicular Lymphoma Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Epcoritamab Domain Hematology Reason of inclusion Indication extension IND Main indication Indolent non-Hodgkin’s lymphoma Extended indication 2L Follicular Lymphoma Current proprietary name Already available biosimilars / generics Proprietary name Tepkinly Manufacturer Abbvie Portfolio holder Abbvie Mechanism of action Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date 2026 Expected Registration 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Broadly excluded Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Verdere resultaten dienen afgewacht te worden om een uitspraak over de therapeutische waarde te doen. Duration of treatment Frequency of administration Dosage per administration References NCT05409066 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References https://iknl.nl/kankersoorten/hemato-oncologie/nkr-cijfers/fl Additional remarks In Nederland krijgen jaarlijks zo’n 550 mensen de diagnose folliculair lymfoom (FL). Een deel daarvan komt later in tweedelijns behandeling (2L).De geschatte totale prevalentie ligt rond de 5.600 patiënten. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks